A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Status:
Recruiting

Trial end date:
2027-05-08

Target enrollment:

Participant gender:

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Phase 3

Incyte Corporation